Biochemical Safety of Ablative Yttrium-90 Radioembolization for Hepatocellular Carcinoma as a Function of Percent Liver Treated

Cynthia De la Garza-Ramos 1,*, Cameron J Overfield 1,*, S Ali Montazeri 1, Harris Liou 2, Ricardo Paz-Fumagalli 1, Gregory T Frey 1, J Mark McKinney 1, Charles A Ritchie 1, Andrew R Lewis 1, Denise M Harnois 3, Tushar Patel 3, Beau B Toskich 1

1Division of Interventional Radiology, Mayo Clinic Florida, Jacksonville, FL, USA; 2Alix School of Medicine, Mayo Clinic Arizona, Scottsdale, AZ, USA; 3Department of Transplant, Mayo Clinic Florida, Jacksonville, FL, USA

*These authors contributed equally to this work

Purpose: Transarterial radioembolization can serve as an ablative therapy for early-stage hepatocellular carcinoma (HCC). Given the volumetric variability of liver segments, this study aimed to characterize the safety of ablative radioembolization by determining percent liver treated (%LT) thresholds associated with biochemical toxicity.

Patients and Methods: Patients with HCC receiving a single ablative radioembolization treatment using glass microspheres from 2017 through 2020 were reviewed. %LT was calculated as treatment angiosome volume divided by whole liver volume. Biochemical toxicities were defined as increases in Albumin-Bilirubin (ALBI) grade or Child-Pugh (CP) class compared to baseline and albumin or bilirubin adverse events (AEs) per the Common Terminology Criteria for Adverse Events. Receiver operating characteristic curves and multivariate logistic regression analyses were performed to assess the impact of %LT on toxicities.

Results: Of 141 patients analyzed, 53% (n=75) were ALBI 1, 45% (n=64) ALBI 2, 79% (n=111) CP-A, and 21% (n=30) CP-B. A %LT ≥14.5% was associated with grade/class increases in ALBI 2 (p≤0.01) and CP-B patients (p=0.026). In multivariate analysis, a %LT ≥14.5% was an independent predictor of increases in the ALBI 2 and CP-B groups (p<0.01). No significant %LT threshold was found for ALBI 1 and CP-A patients. No grade 3/4 albumin or bilirubin AEs were reported, while grade 2 AEs were related to an initial whole liver volume <1.3 L (p≤0.01).

Conclusion: Patients with ALBI 2 and CP-B liver function are less likely to have an increase in their respective grade/class when treating <14.5% of the liver using glass microspheres. ALBI 1 and CP-A patients showed no definitive %LT threshold for biochemical toxicity within the range of this study.

Keywords: hepatocellular carcinoma, radioembolization, Y-90, adverse events

Plain Language Summary

Transarterial radioembolization with ablative doses (>190 Gy) of Yttrium 90 is an effective therapy for early-stage hepatocellular carcinoma. This study found that treatments targeting ≥14.5% of the liver can predispose patients with a baseline ALBI 2 or Child-Pugh B classification to develop worsening of their liver function by 3- and 6 months post-procedure. Patients with a total liver volume <1.3 L are more likely to exhibit moderate bilirubin or albumin adverse events.

Introduction

Transarterial radioembolization (TARE) with Yttrium-90 (90Y) has emerged as a versatile treatment for patients with hepatocellular carcinoma (HCC), with...
neoadjuvant, definitive, and palliative applications.\textsuperscript{1–5} Selective delivery of high dose TARE to ≤2 hepatic segments (ie, radiation segmentectomy) has shown local tumor control and survival outcomes comparable to other modalities with curative intent.\textsuperscript{6–8} Radiation segmentectomy with a single compartment Medical Internal Radiation Dose (MIRD) ≥190 Gy correlates with pathologic tumor necrosis with little to no exposure to the adjacent non-target normal parenchyma.\textsuperscript{9–11}

Despite the documented efficacy and safety of segmental ablative TARE, the quantitative amount of liver that can be treated with ablative doses of \textsuperscript{90}Y remains to be determined. Considering the variability of treatment volumes and underlying liver function in this patient population, establishing toxicity thresholds for percent liver treated (\%LT) is warranted. This study aimed to characterize the biochemical safety of ablative TARE with a single compartment MIRD dose ≥190 Gy as a function of \%LT and describe toxicity trends according to the widely utilized hepatic function scoring systems (ie, Albumin-Bilirubin (ALBI) grade and Child-Pugh (CP) class). Additional associations between treatment parameters and development of biochemical toxicities were sought. A subanalysis with an MIRD dose ≥400 Gy was also performed.

**Patients and Methods**

**Patient Selection**

This study received Institutional Review Board approval and the requirement for written informed consent was waived. A retrospective chart review was performed on patients with HCC treated at a tertiary care center with TARE from January 2017 through October 2020. All patients received TARE as advised by a multidisciplinary tumor board. Inclusion criteria were primary HCC diagnosis by radiologic criteria or histopathology, a single radioembolization treatment, total single compartment MIRD ≥190 Gy, no additional locoregional interventions during the first year post-TARE, and available data for at least one of the 3-, 6- or 12-month follow-up periods. Patient baseline variables included age, sex, BMI, etiology of liver disease, Barcelona Clinic Liver Cancer (BCLC) stage, Eastern Cooperative Oncology Group (ECOG) performance status, CP class, ALBI grade and score, and Model for End-Stage Liver Disease (MELD) score. Patients were censored by time of liver transplantation, anatomic resection, or death. Those without the aforementioned events were censored at time of last encounter.

**Radioembolization**

Baseline magnetic resonance imaging (MRI), or contrast tomography (CT) if MRI was contraindicated, was obtained within 30 days prior to TARE. Radioembolization procedures were performed by seven experienced interventional radiologists using \textsuperscript{90}Y glass microspheres (Therasphere\textsuperscript{TM}, Boston Scientific, Marlborough, MA) as previously published.\textsuperscript{12} Pre-treatment mapping angiography using selective contrast-enhanced cone-beam CT (ce-CBCT) was performed to determine target angiosomes supplying tumor. Intraarterial injection of technetium-99m labeled macroaggregated albumin with subsequent planar and single photon emission computed tomography was obtained to visualize radiotracer deposition and calculate lung shunt fractions. Dosimetry was calculated as per the single compartment MIRD model. All angiosomes received ≥190 Gy. In instances with multivessel administrations, MIRD was calculated using the cumulative treatment activity and volume.

**Percent Liver Treated Calculation**

Pre-TARE whole liver volume calculation was performed using Visage version 7.1.14 (Visage Imaging, San Diego, CA) based on the baseline MRI or CT. Treatment angiosome volume, defined as the volume of the angiosome or sum of multiple angiosomes targeted for radiation, was obtained from the pre-TARE ce-CBCT. \%LT was calculated as treatment angiosome volume divided by pre-TARE whole liver volume.

**Follow-Up and Toxicity Analysis**

All patients were assessed for adverse events (AEs) via phone calls at 24 hours and two weeks after the intervention. Clinical visitation, imaging and laboratory testing were performed at one month followed by every three months during the first year post-TARE. ECOG, albumin, bilirubin, creatinine, sodium, International Normalized Ratio, platelet count, absolute lymphocyte count, and the presence of ascites (defined as any accumulation detected via follow-up imaging or physical examination) and/or encephalopathy at baseline and 3-, 6-, and 12-months post-intervention were obtained from the medical records. The corresponding parameters were used to calculate the CP class, ALBI grade and score, and MELD scores at each
time point. Procedure-related AEs were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.13

Statistical Analysis
Patient characteristics, laboratory and treatment parameters were reported as median (interquartile range (IQR) 25, 75) for continuous variables, and frequency (percentage) for categorical variables. Laboratory data pre- and post-TARE were compared using Friedman test. Additional analysis was performed using Wilcoxon signed-rank test for pre-intervention and each of the post-intervention measures. Categorical variables were compared using the Chi-squared or Fisher’s exact test, as appropriate.

The biochemical toxicity events based on the hepatic function scoring systems were defined as increases in ALBI grade compared to baseline (ie, grade 1 to 2/3, or 2 to 3), and increases from CP-A to B/C or CP-B to C, respectively. Analysis using the MELD score could not be performed due to missing data. To determine treatment parameter thresholds for which events were observed per baseline grade/class during the follow-up periods, receiver operating characteristic (ROC) curves were used. The independent parameters included treatment angiosome volume, whole liver volume, %LT, total MIRD dose, treatment activity, total sphere number, specific activity, and number of spheres per cc. Threshold values were determined where the sum of sensitivity and specificity was highest (maximum Youden index). This was performed only for the 3- and 6-month follow-ups, as this period was previously shown to capture procedure-related decompensations, while 12-month follow-up may be influenced by natural progression of liver disease.14 Following the previously described methodology, ROC curve analysis to determine the relation of treatment parameters with the development of the highest reported grade of albumin or bilirubin toxicities per CTCAE criteria was performed.

The treatment parameter with the highest accuracy to predict toxicity events until 6 months (ie, %LT) was incorporated in the multivariate logistic regression analyses. To determine the average effect of any significant %LT thresholds on the change in ALBI grade or CP class in all follow-ups, the generalized estimating equations method was used.15,16 This method was chosen as its methodology allows for the inclusion of all patients with available data for the outcome studied, without excluding those who missed or had not reached at least one of the follow-up periods. The dependent variable was defined as increased ALBI grade or CP class. The independent variables were %LT, specific activity, time, and baseline grade/class for their corresponding models. The models included specific activity (calculated as treatment activity divided by number of spheres) as this treatment parameter did not exhibit a correlation with %LT, while other relevant parameters (ie, treatment activity) exhibited a positive correlation and could lead to confounding. The parameter of time represented the multiple follow-up periods.

As a secondary endpoint, overall survival (OS) was analyzed using Kaplan-Meier curves with Log rank test for the entire cohort by ALBI grade, as well as each grade subgroup for comparison based on the established %LT threshold. All statistical analyses were conducted using SPSS version 25.0 for Windows (Armonk, NY: IBM Corp.) with statistical significance defined as a p-value <0.05.

Results
Patient and Treatment Characteristics
Fifty-two percent (n=141) out of 271 patients with HCC treated with ablative TARE during the study period met inclusion criteria. Baseline characteristics of the 141 patients included for analysis are summarized in Table 1. Median age was 68 years (range: 38–92) and 78% (n=111) were male. The most common sole predisposing risk factor for HCC was HCV (35%; n=49). Sixty-two percent (n=87) of patients were classified as BCLC stage 0-A, 17% (n=24) BCLC B, and 21% (n=30) BCLC C. ALBI grade distribution was 53% (n=75) ALBI 1 and 45% (n=64) ALBI 2. CP class distribution was 79% (n=111) CP-A and 21% (n=30) CP-B. Median ALBI and MELD scores were –2.61 (IQR –2.95, –2.13) and 9 (IQR 7, 11), respectively. Medically controlled ascites was present at the time of the intervention in 8% (n=12) of patients, and encephalopathy in 16% (n=23). A total of 6% (n=8) of patients had a pre-existing transjugular intrahepatic portosystemic shunt. During the study period, 17% (n=24) of patients received subsequent systemic therapy; 21% (n=5) with tyrosine kinase inhibitors, 50% (n=12) with immunotherapy, and 29% (n=7) received both. At last follow-up, 30% (n=43) of patients had undergone liver transplantation, and 2% (n=3) received resection.

All targeted angiosomes were administered a total MIRD dose ≥190 Gy, with a median dose of 403 Gy (IQR 303, 522; range: 190–1100) as shown in Table 2. The median treatment angiosome volume was 215 cm³ (IQR 115, 381; range: 30–1410), median whole liver...
Table 1 Patient Baseline Characteristics

| Parameter (n = 141) | Median (IQR 25, 75) or n (%) |
|---------------------|-----------------------------|
| Age | 68 (64, 73) |
| Sex | Female 31 (22) Male 111 (78) |
| BMI | 29.8 (26.1, 34.4) |
| Etiology | HCV 49 (35) NASH/NAFLD 39 (28) Multiple 22 (16) Alcohol 14 (10) Other 17 (12) |
| BCLC | 0-A 87 (62) B 24 (17) C 30 (21) |
| ECOG | 0 118 (84) 1 20 (14) 2 3 (2) |
| ALBI grade | 1 75 (53) 2 64 (45) 3 2 (1) |
| Child-Pugh class | A 111 (79) B 30 (21) C 0 |
| ALBI score | −2.61 (−2.95, −2.13) |
| MELD score | 9 (7, 11) |
| Albumin (g/dl) | 3.9 (3.5, 4.3) |
| Bilirubin (mg/dl) | 0.8 (0.6, 1.2) |
| Lymphocyte count (x 10⁹/L) | 1.11 (0.69, 1.69) |
| Platelet count (x 10⁹/L) | 105 (74, 158) |
| INR | 1.2 (1.1, 1.2) |
| Ascites | 12 (8) |
| Encephalopathy | 23 (16) |

Table 2 Treatment Characteristics

| Variable (n = 141) | Median (IQR 25, 75) or Range |
|---------------------|-----------------------------|
| Treatment angiosome volume (mL) | 1698 (1362, 2094) |
| Whole liver volume (mL) | 1698 (1362, 2094) |
| Percent liver treated (%) | 12.6 (7.3, 21.7) |
| Total MIRD dose (Gy) | 403 (303, 522) |
| Treatment activity (GBq) | 1.67 (0.94, 2.84) |
| Lung dose (Gy) | 1.31 (0.66, 3.17) |
| Lung shunt fraction (%) | 1.6 (1.0, 2.8) |
| Total sphere number (million) | 4.0 (2.4, 6.0) |
| Specific activity (Bq) | 527 (319, 700) |
| Spheres per cc (thousands) | 17 (13, 26) |

Procedure-Related Adverse Events

There were no major procedure-related complications. None of the patients exhibited radiation pneumonitis. Trends on laboratory and clinical parameters across follow-up periods are detailed in Table 3. Statistically significant differences in ALBI, MELD, albumin, lymphocyte count, and INR were observed at each follow-up compared to baseline, with a similar trend for total bilirubin at 3 and 12 months. Compared to baseline, 22.7% (n=32/141) of patients developed ascites by 3 months, however, this finding was most commonly perilesional and without associated sequelae and decreased to 17% (n=24) and 9% (n=9) by 6 and 12 months, respectively. Eighteen percent (n=26/141) of patients had newly documented symptoms of encephalopathy by 3-month follow-up, which reduced to 11% (n=16) and 6% (n=9) by 6 and 12 months, respectively.

ALBI grade increases compared to baseline were documented in 21% (n=28/134) of patients (baseline ALBI 1: 28%, n=20/71; ALBI 2: 13%, n=8/63) at the 3-month follow-up, 22% (n=23/104) by 6 months (ALBI 1: 29%, n=17/59; ALBI 2: 13%, n=6/45), and 25% (n=14/56) at 12 months (ALBI 1: 28%, n=10/35; ALBI 2: 19%, n=4/21). CP class increases were observed in 22% (n=24/109) at 3 months (CP-A: 23%, n=18/79; CP-B: 20%, n=6/30), 18% (n=16/91) at 6 months (CP-A: 16%, n=12/73; CP-B: 22%, n=4/18), and 31% (n=13/42) at 12 months (CP-A: 26%, n=9/34; CP-B: 50%, n=4/8).

Per CTCAE v5.0 criteria, no grade 3/4 albumin or bilirubin toxicities were reported at 3- and 6-month follow-up (Table 4). The highest documented albumin or bilirubin AEs within 6 months post ablative TARE...
Table 3 Laboratory and Clinical Parameters at Baseline and Available Data at 3-, 6-, and 12-Month Follow-Up

| Parameter          | Median (IQR 25, 75) or n (%)       |
|--------------------|-----------------------------------|
|                    | Baseline | 3 Months | 6 Months | 12 Months | p       |
| ALBI score         | -2.61 (-2.95, -2.13)              | -2.38 (-2.88, -2.04)*            | -2.54 (-2.94, -2.10)*            | -2.64 (-3.02, -2.01)*          | 0.007   |
| MELD score         | 9 (7, 11)                           | 10 (7, 14)*                       | 10 (7, 12)*                       | 11 (8, 15)*                      | <0.001  |
| Albumin (g/dl)     | 3.9 (3.5, 4.3)                     | 3.8 (3.3, 4.2)*                   | 3.8 (3.4, 4.2)*                   | 4.0 (3.4, 4.3)*                  | <0.001  |
| Bilirubin (mg/dl)  | 0.8 (0.6, 1.2)                     | 0.9 (0.6, 1.5)*                   | 0.7 (0.5, 1.4)                    | 0.8 (0.5, 1.5)*                   | 0.062   |
| Lymphocyte count (x 10⁹/L) | 1.11 (0.69, 1.69)                     | 0.60 (0.42, 0.90)*              | 0.76 (0.53, 1.10)*              | 0.88 (0.52, 1.10)*              | 0.001   |
| Platelet count (x 10⁹/L) | 105 (74, 158)                        | 93 (61, 161)                     | 102 (67, 166)                     | 96 (74, 145)                     | 0.147   |
| INR                | 1.2 (1.1, 1.2)                     | 1.2 (1.1, 1.4)*                   | 1.2 (1.1, 1.3)*                   | 1.2 (1.1, 1.3)*                   | 0.009   |
| Ascites            | 12 (8)                             | 41 (29)                           | 31 (22)                           | 18 (13)                           |         |
| Encephalopathy     | 23 (16)                             | 45 (33)                           | 30 (21)                           | 14 (10)                           |         |

Notes: *Statistically significant difference compared to baseline. Continuous variables pre- and post-intervention were compared with Friedman test, with post hoc analysis using Wilcoxon signed-rank test for pre-intervention and each post-intervention measure.

**Abbreviations:** IQR, interquartile range; ECOG, Eastern Cooperative Oncology Group; ALBI, albumin-bilirubin; MELD, Model for End-Stage Liver Disease; INR, International Normalized Ratio.

Table 4 Frequency of Biochemical Adverse Events per Follow-Up Period According to the Common Terminology Criteria for Adverse Events V5.0

| Parameter          | Grade | 3 Months | 6 Months | 12 Months |
|--------------------|-------|----------|----------|-----------|
| Albumin            | Grade 1 | 28 (20) | 19 (13) | 13 (9) |
|                    | Grade 2 | 14 (10) | 9 (6)   | 4 (3)   |
|                    | Grade 3 | 0       | 0       | 0       |
|                    | Grade 4 | 0       | 0       | 0       |
| Bilirubin          | Grade 1 | 28 (20) | 19 (13) | 9 (7)   |
|                    | Grade 2 | 9 (6)   | 6 (4)   | 5 (3)   |
|                    | Grade 3 | 0       | 0       | 2 (1)   |
|                    | Grade 4 | 0       | 0       | 0       |
| Absolute lymphocyte count | Grade 1 | 11 (8) | 13 (9) | 4 (3) |
|                    | Grade 2 | 33 (23) | 27 (19) | 9 (6) |
|                    | Grade 3 | 34 (24) | 15 (11) | 6 (4) |
|                    | Grade 4 | 2 (1)   | 2 (1)   | 1 (1)   |
| Platelet count     | Grade 1 | 41 (29) | 35 (25) | 23 (16) |
|                    | Grade 2 | 26 (18) | 21 (15) | 9 (6)   |
|                    | Grade 3 | 14 (10) | 9 (6)   | 4 (3)   |
|                    | Grade 4 | 1 (1)   | 0       | 1 (1)   |

Notes: Percent Liver Treated.

were grade 2, with a frequency of 16% (n=23) at 3- and 10% (n=15) at 6 months. Grade 3/4 lymphocyte and platelet toxicities were observed at 3 months in 25% (n=36) and 11% (n=15) of patients, respectively, and at 6 months in 12% (n=17) and 6% (n=9). ROC curves to determine the relation of treatment variables with the development of grade 2 albumin or bilirubin toxicities for all patients revealed an association with a whole liver volume ≤1347 cm³ at 3-month (AUC: 0.29 (95% CI: 0.14–0.44); sensitivity: 64% and specificity: 80%; p=0.010) and ≤1302 cm³ at 6-month follow-up (AUC: 0.23 (95% CI: 0.07–0.40); sensitivity: 67% and specificity: 81%; p=0.008) (Supplementary Table 1). A %LT threshold of ≥14.5% was related to the development of these events as a trend at 3 months (p=0.201) and achieved statistical significance at 6 months (AUC: 0.75 (95% CI: 0.62–0.89); sensitivity: 89% and specificity: 65%; p=0.012).

Biochemical Trends as a Function of Percent Liver Treated

ROC curve analyses on the relation of treatment variables to increases in ALBI grade and CP class per baseline classification revealed %LT as the only parameter significantly related to toxicity events in both scoring systems. The %LT threshold was ≥14.5% for the baseline ALBI 2 group at 3 months (AUC: 0.84 (95% CI: 0.69–0.99); sensitivity: 87% and specificity: 73%; p=0.002) and 6 months (AUC: 0.83 (95% CI: 0.67–0.99); sensitivity: 83% and specificity: 79%; p=0.010) (Supplementary Table 2), as well as the CP-B group as a trend at 3 months (p=0.87) and reached statistical significance at 6 months (AUC: 0.87 (95% CI: 0.71–1.00); sensitivity: 100% and specificity: 85%; p=0.026) (Supplementary Table 3). For patients with a baseline ALBI 2 events at 3 months were additionally associated with a treatment angiosome volume ≥246 cm³ (p=0.005), treatment activity ≥2.61 GBq (p=0.001), and total sphere number ≥3.6 million (p=0.019). For the baseline CP-A group, a whole liver volume ≤1714 cm³ correlated with class increases at 6 months (p=0.024). No significant associations were found.
Table 5 Multivariate Logistic Regression Analysis Using Generalized Estimating Equations (GEE) Method to Explore the Odds of Increase in ALBI Grade and Child-Pugh Class

| Baseline | Predictors | Odds Ratio | 95% CI  | p     |
|----------|------------|------------|---------|-------|
| Increase in ALBI grade |            |            |         |       |
| ALBI 2   | %LT ≥14.5% | 8.11       | 2.14–30.75 | 0.002 |
|          | %LT <14.5% | Ref        |         |       |
|          | Time       | 1.54       | 0.83–2.87 | 0.172 |
|          | Specific activity | 1.00     | 1.00–1.00 | 0.442 |
| Increase in CP class |            |            |         |       |
| CP-B     | %LT ≥14.5% | 23.02      | 2.63–201.16 | 0.005 |
|          | %LT <14.5% | Ref        |         |       |
|          | Time       | 4.00       | 1.35–11.89 | 0.013 |
|          | Specific activity | 1.00     | 1.00–1.00 | 0.568 |

Abbreviations: CI, confidence interval; ALBI, albumin-bilirubin; %LT, percent liver treated; CP, Child-Pugh; Ref, reference group.

between treatment parameters and events in the baseline ALBI 1 group.

Multivariate logistic regression analyses on the significant %LT thresholds obtained from the ROC curves revealed significant odds ratios for grade/class increases in patients in the baseline ALBI 2 (p=0.002) or CP-B (p=0.005) groups and a %LT ≥14.5% compared to patients within these classifications with smaller targeted volumes (Table 5). Patients with a baseline CP-B liver function had increased odds of decompensation to CP-C during the follow-up time independent of the treatment, representing natural progression of disease (p=0.013).

Survival Outcomes
Mean follow-up was 13.2 months (95% CI: 11.7–14.8) censored for liver transplantation or anatomic resection. Median OS per ALBI grade was not reached for the ALBI 1 group, while median OS for ALBI 2 patients was 21.5 months (95% CI: 12.6–39.7) (p<0.001).

Subanalysis stratifying patients by %LT above and below the established threshold of 14.5% did not demonstrate differences in OS in either the ALBI 1 (p=0.62) or ALBI 2 groups (p=0.17).

Demises were documented in 19% (n=27) during the study period, none of which were related to TARE. Causes of death for the patients included: progressive or metastatic HCC (37%; n=10), decompensated end-stage liver disease (26%; n=7), additional primary cancer (22%; n=6), and unspecified (15%; n=4).

Subanalysis on Biochemical Toxicities with a Total MIRD ≥400 Gy
Seventy-two patients received a total MIRD ≥400 Gy, with the baseline scoring system distribution as follows: 53% (n=38) ALBI 1, 46% (n=33) ALBI 2, 74% (n=53) CP-A, and 26% (n=19) CP-B. At 3-month follow-up, grade/class increases were documented in 28% (n=10/36) baseline ALBI 1, 15% (n=5/33) ALBI 2, 27% (n=11/41) CP-A, and 21% (n=4/19) CP-B. At 6-month follow-up, events were reported in 35% (n=11/31) ALBI 1, 13% (n=3/23) ALBI 2, 15% (n=5/34) CP-A, and 9% (n=1/11) CP-B. A %LT threshold ≥25% was associated with increases at 3 months in the baseline ALBI 2 group treated with doses ≥400 Gy (AUC: 0.871 (95% CI: 0.68–1.00); sensitivity: 80% and specificity: 96%; p=0.009). No significant %LT thresholds were found for other categories.

Discussion
Due to inadequate liver remnant, portal hypertension, poor liver function, or comorbidities, not all patients are candidates for surgical treatment of HCC. Tumor size, location, and multifocality can also result in ineligibility for thermal ablation. TARE with selectively delivered ablative doses of 90Y containing glass microspheres is an effective therapy for early-stage HCC which has been recently approved by the US Food and Drug Administration. Due to gradual parenchymal devitalization over several months, TARE allows for the safe ablation of hepatic volumes equivalent to an anatomic resection without the instantaneous loss of liver function and sinusoidal reserve. While general safety has been established when treating two Couinaud segments or less, a more granular understanding of how much liver can be treated as a function of hepatic substrate has not been established. Furthermore, the volumetric variability of hepatic segments is well recognized; segment VIII may represent up to 26% of the total liver volume, while each of segments I, II, III and VI tend to represent <10%. Given the high variability of hepatic segmental volume and treatment angiosomes between individuals, thresholds for %LT that can be safely treated with ablative TARE, defined as a single compartment MIRD dose >190 Gy, would aid in predicting AEs and guiding risk stratification.

While radioembolization-induced liver disease (REILD) has been reported in up to 20% of patients who received conventional, palliative dose TARE, this is most often observed in those with preexisting liver dysfunction...
and in bilobar treatments. The toxicities of large volume radioembolization that fall outside of classically defined REILD, such as aggravation of portal hypertension with otherwise preserved liver synthetic function, are less well documented. Conversely, the initial experience with radiation segmentectomy described no incidence of the classic REILD, with grade 3/4 AEs occurring in approximately 9% of patients within 3 months post-treatment.

Ablative radioembolization is known to be generally well tolerated; however, it is important to establish predictability for this therapy. Under current liver transplant allocation rules, patients are now subjected to an extended dictability for this therapy. Under current liver transplant allocation rules, patients are now subjected to an extended biological test of time, up and above the prior 6 months, leading to a longer surveillance period. As such, local therapy AEs that would preclude patients from future standard-of-care treatment should be considered with caution.

This study sought to establish safety %LT thresholds relative to hepatic substrate according to the widely utilized liver scoring systems (ie, ALBI grade and CP class) to better personalize risk stratification. Overall, increases in ALBI grade or CP class by 3 and 6 months occurred in 18–22% of patients. Ablative TARE targeting ≥14.5% of the liver was associated with more toxicity in patients with a baseline ALBI 2 or CP-B hepatic function compared to those with smaller targeted volumes. While increases in grade or class occurred in those with a baseline ALBI 1 (3 months: 28%; 6 months: 29%) and CP-A (3 months: 23%; 6 months: 16%), a %LT threshold could not be identified in these patients within the treatment range of this study. Notably, OS was not significantly different in any study group when comparing those treated for <14.5% vs ≥14.5% of the liver. For patients with a baseline ALBI 2, grade increases by 3 months were additionally associated with a %LT ≥14.5% when applied to the study sample size and should be interpreted with caution. Otherwise, no distinct %LT thresholds associated with a grade or class increase in baseline CP-B patients (vs 14.5% with a MIRD ≥190 Gy), which could be related to insufficient sample size and should be interpreted with caution. Otherwise, no distinct %LT thresholds associated with increased risk of hepatotoxicity could be found within this subgroup. Associations with other treatment variables (ie, treatment activity, total sphere number, specific activity, spheres per cc) and AEs were also sought, yet no relationship was found.

Advances in the understanding of radioembolization dosimetry have led to both safer practice and improved tumor control. Despite these developments, radioembolization dosimetry remains leveraged on large assumptions inherent to compartmental dosimetry as the ability to resolve true microsphere brachytherapy dose is not currently feasible in vivo. Further compounding these assumptions are the radiation dose microenvironment variables generated by differences in particle density and specific activity, tumor angiogenesis, as well as tumor biology and liver reserve. As such, future improvements in dosimetry will likely be leveraged either on superior microsphere dose simulation or on establishing stronger normative experiences within current dose methodologies, regardless of their limitations.

Limitations to this study include its retrospective nature, as not all subjects had consistently timed laboratory tests in follow-up. The established follow-up periods created a potential guarantee-time bias, despite reported causes of demise for excluded patients. Generating %LT threshold analysis by baseline hepatic function grade or
class subdivides an otherwise larger cohort and limits statistical power. Considering the expected yet variable progression of chronic liver disease, it is difficult to discern treatment toxicities from natural changes in liver function. The authors recognize the importance of clinical toxicities aside from biochemical AEs, which have been described in the literature and were not within the scope of this study. MIRD methodology incorrectly assumes uniform distribution of radiation between the tumor and liver parenchyma, yet existing safety and outcomes data, as well as the recommendation for this dose methodology in the glass microsphere instructions for use, support its use in this study. It is probable that the dose ranges analyzed in this report, if rendered into normal tissue and tumor compartments, would surpass established ablative thresholds for both (>88 and >205 Gy, respectively). Despite interest in determining a possible association between number of spheres per cc of liver and biochemical safety, this analysis could not be adequately powered due to variable %LT. This study did not analyze other radioembolization devices or non-hepatocellular malignancies and its findings may not be applicable to these circumstances.

Conclusion
Treating primary HCC with ablative radioembolization using $^{90}$Y containing glass microspheres is generally well tolerated and results in low levels of AEs. ALBI 2 and CP-B patients are less likely to sustain biochemical toxicity with a targeted %LT <14.5% with treatment doses ≥190 Gy. No definitive %LT threshold was associated with biochemical toxicity in ALBI 1 and CP-A patients within the range of this study. The development of grade 2 (ie, moderate) albumin or bilirubin AEs is more common in patients with an initial whole liver volume <1.3 L.

Abbreviations
AE, adverse event; ALBI, Albumin-Bilirubin; BCLC, Barcelona Clinic Liver Cancer; Ce-CBCT, Contrast-enhanced cone-beam computed tomography; CP, Child-Pugh; CT, computed tomography; CTCAE, Common Terminology Criteria for Adverse Events; ECOG, Eastern Cooperative Oncology Group; HCC, hepatocellular carcinoma; IQR, interquartile range; MELD, Model for End-Stage Liver Disease; MIRD, Medical Internal Radiation Dose; MRI, magnetic resonance imaging; OS, overall survival; %LT, percent liver treated; REILD, radioembolization induced liver disease; ROC, receiver operating characteristic; TARE, transarterial radioembolization; $^{90}$Y, yttrium-90.

Ethical Approval and Informed Consent
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All liver donations were performed voluntarily with written informed consent and conducted in accordance with the Declaration of Istanbul. This retrospective, minimal risk study was approved by the Institutional Review Board (IRB) at Mayo Clinic and the requirement to obtain written informed consent was waived. Confidentiality of all collected patient data was maintained.

Consent for Publication
For this type of study consent for publication is not required.

Author Contributions
All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Funding
This study did not receive financial support.

Disclosure
BB Toskich is an advisor for Boston Scientific, Sirtex Medical, Johnson and Johnson, AstraZeneca, Genentech, Eisai, HistoSonics and Turnstone Biologics. The authors reported no other potential conflicts of interest for this work.

References
1. Gabr A, Kulik L, Mouli S, et al. Liver transplantation following yttrium-90 radioembolization: 15-year experience in 207-patient cohort. *Hepatology*: 2020;73(3):998–1010. doi:10.1002/hep.31318
2. Parikh ND, Waljee AK, Singal AG. Downstaging hepatocellular carcinoma: a systematic review and pooled analysis. Liver Transplant. 2015;21(9):1142–1152. doi:10.1002/lt.24169

3. Shehta A, Lee J-M, Suh K-S, et al. Bridging and downstaging role of trans-arterial radio-embolization for expected small remnant volume before liver resection for hepatocellular carcinoma. Ann Hepatobiliary Pancreatic Surg. 2020;24(4):421–430. doi:10.14701/ahbps.2020.24.4.421

4. Teyateeti A, Mahvash A, Long JP, et al. Survival outcomes for yttrium-90 transarterial radioembolization with and without sorafenib for unresectable hepatocellular carcinoma patients. J Hepatocell Carcinoma. 2020;7:117–131. doi:10.2147/JHC.S248314

5. Toskich B, Patel T. Radioembolization for hepatocellular carcinoma: the time has come. Hepatology. 2018;67(3):820–822. doi:10.1002/hep.29590

6. Lewandowski RJ, Gabr A, Abouchaleh N, et al. Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma. Radiology. 2018;287(3):1050–1058. doi:10.1148/radiol.2018171678

7. Biederman DM, Titano JJ, Bishay VL, et al. Radiation segmentectomy versus TACE combined with microwave ablation for unresectable solitary hepatocellular carcinoma up to 3 cm: a propensity score matched study. Radiology. 2017;283(3):895–905. doi:10.1148/radiol.2016160718

8. Arndt L, Villalobos A, Wagstaff W, et al. Evaluation of medium-term efficacy of Y90 radiation segmentectomy vs percutaneous microwave ablation in patients with solitary surgically unresectable < 4 cm hepatocellular carcinoma: a propensity score matched study. Cardiovasc Intervent Radiol. 2021;44(3):401–413. doi:10.1007/s00270-020-02712-1

9. Vouche M, Habib A, Ward TJ, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology. 2014;60(1):192–201. doi:10.1002/hep.27057

10. Riaz A, Gates VL, Atassi B, et al. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. Int J Radiat Oncol Biol Phys. 2011;79(1):163–171. doi:10.1016/j.ijrobp.2009.10.062

11. Toskich B, Vidal LL, Olson MT, et al. Pathologic response of hepatocellular carcinoma treated with Yttrium-90 glass microsphere radioembolization prior to liver transplantation: a validation study. J Vasc Interv Radiol. 2021;32(4):518–526.e1. doi:10.1016/j.jvir.2020.12.019

12. Toskich BB, Liu DM. Y90 radioembolization dosimetry: concepts for the interventional radiologist. Tech Vasc Interv Radiol. 2019;22(2):100–111. doi:10.1053/j.tvir.2019.02.011

13. National Cancer Institute (US). Citation Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events (CTcae). v.5.0. Cancer Therapy Evaluation Program; 2017.

14. Chiesa C, Mira M, Bhooi S, et al. Radioembolization of hepatocarcinoma with (90)Y glass microspheres: treatment optimization using the dose-toxicity relationship. Eur J Nucl Med Mol Imaging. 2020;47(13):3018–3032. doi:10.1007/s00259-020-04845-4

15. Hubbard AE, Ahern J, Fleischer NL, et al. To GEE or not to GEE: comparing population average and mixed models for estimating the associations between neighborhood risk factors and health. Epidemiology. 2010;21(4):467–474. doi:10.1097/EDE.0b013e3181caeb90

16. Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73(1):13–22. doi:10.1093/biomet/73.1.13

17. O’Leary C, Mahler M, Soulen MC. Curative-intent therapies in localized hepatocellular carcinoma. Curr Treat Options Oncol. 2020;21(4):31. doi:10.1007/s11664-020-0725-3

18. Salem R, Johnson GE, Kim E, et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable hepatocellular carcinoma: the LEGACY study. Hepatology. 2021;0:1-11. doi:10.1002/hep.31819

19. Food and Drug Administration USD of H and HS. TheraSphere™... P200029; 2020. Available from: https://www.fda.gov/medical-devices/recently-approved-devices/theraspheretm-p200029. Accessed April 25, 2021

20. Mise Y, Satou S, Shindoh J, et al. Three-dimensional volumetry in 107 normal livers reveals clinically relevant inter-segment variation in size. HPB (Oxford). 2014;16(5):439–447. doi:10.1111/hpb.12157

21. Riaz A, Lewandowski RJ, Kulik LM, et al. Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J Vasc Interv Radiol. 2009;20(9):1121–1130;quiz 1131. doi:10.1016/j.jvir.2009.05.030

22. Tomozawa Y, Jahangiri Y, Pathak P, et al. Long-term toxicity after transarterial radioembolization with yttrium-90 using resin microspheres for neuroendocrine tumor liver metastases. J Vasc Interv Radiol. 2018;29(6):858–865. doi:10.1016/j.jvir.2018.02.002

23. Sangro B, Gil-Alzugaray B, Rodriguez J, et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer. 2008;112(7):1538–1546. doi:10.1002/cncr.23339

24. Organ Procurement and Transplantation Network USD of H and HS. Organ Procurement and Transplantation Network (OPTN) policies. 2020. Available from: https://www.hhs.gov/guidance/sites/default/files/hhs-guidance-documents/optn_policies.pdf. Accessed April 27, 2020

25. Salem R, Lewandowski RJ, Atassi B, et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol. 2005;16(12):1627–1639. doi:10.1016/j.jvir.2005.01.007

26. Li X, Montazeri SA, Paz-Fumagalli R, et al. Prognostic significance of neutrophil to lymphocyte ratio dynamics in patients with hepatocellular carcinoma treated with radioembolization using glass microspheres. Eur J Nucl Med Mol Imaging. 2021;48:2624–2634. doi:10.1007/s00259-020-05186-y

27. Gabr A, Riaz A, Johnson GE, et al. Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants. Eur J Nucl Med Mol Imaging. 2021;48(2):580–583. doi:10.1007/s00259-020-04976-8

28. Paldar X, Edeline J, Rolland Y, et al. Dosimetric parameters predicting contralateral liver hypertrophy after unilobar radioembolization of hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2018;45(3):392–401. doi:10.1007/s00259-017-3845-7

29. Garin E, Tselikas L, Guix B, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(1):17–29. doi:10.1016/s2468-1253(20)30290-9
